Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.

× No keyword cloud information.

12 in total

1. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects.

Authors: Gerhard J Molderings; Kirsten Meis; Ulrich W Kolck; Jürgen Homann; Thomas Frieling
Journal: Immunogenetics Date: 2010-09-14 Impact factor: 2.846

2. A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis.

Authors: Jean-Emmanuel Kurtz; Irène Asmane; Anne-Claire Voegeli; Agnès Neuville; Armelle Dufresne; Valère Litique; Christine Chevreau; Jean-Pierre Bergerat
Journal: Sarcoma Date: 2010-03-17

3. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.

Authors: A Dufresne; F Bertucci; N Penel; A Le Cesne; B Bui; M Tubiana-Hulin; I Ray-Coquard; D Cupissol; C Chevreau; D Perol; A Goncalves; M Jimenez; P P Bringuier; J Y Blay
Journal: Br J Cancer Date: 2010-07-27 Impact factor: 7.640

4. High-grade soft tissue sarcoma arising in a desmoid tumor: case report and review of the literature.

Authors: François Bertucci; Marjorie Faure; Maria-Rosa Ghigna; Bruno Chetaille; Jérôme Guiramand; Laurence Moureau-Zabotto; Anthony Sarran; Delphine Perrot
Journal: Clin Sarcoma Res Date: 2015-11-30

5. Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.

Authors: Maxim Ivanov; Konstantin Laktionov; Valery Breder; Polina Chernenko; Ekaterina Novikova; Ekaterina Telysheva; Sergey Musienko; Ancha Baranova; Vladislav Mileyko
Journal: J Transl Med Date: 2017-01-31 Impact factor: 5.531

6. Mesenteric fibromatosis after resection for gastrointestinal stromal tumor of stomach: A case report.

Authors: Yiming Chu; Qingqu Guo; Dan Wu
Journal: Medicine (Baltimore) Date: 2017-12 Impact factor: 1.817

7. KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome.

Authors: Mehdi Brahmi; Laurent Alberti; Armelle Dufresne; Isabelle Ray-Coquard; Philippe Cassier; Pierre Meeus; Anne-Valérie Decouvelaere; Dominique Ranchère-Vince; Jean-Yves Blay
Journal: BMC Cancer Date: 2015-10-24 Impact factor: 4.430

8. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.

Authors: Armelle Dufresne; Laurent Alberti; Mehdi Brahmi; Sarah Kabani; Héloïse Philippon; David Pérol; Jean Yves Blay
Journal: BMC Cancer Date: 2014-08-29 Impact factor: 4.430

9. AKT1 and BRAF mutations in pediatric aggressive fibromatosis.

Authors: Cristina Meazza; Antonino Belfiore; Adele Busico; Giulio Settanni; Nicholas Paielli; Luca Cesana; Andrea Ferrari; Stefano Chiaravalli; Maura Massimino; Alessandro Gronchi; Chiara Colombo; Silvana Pilotti; Federica Perrone
Journal: Cancer Med Date: 2016-04-08 Impact factor: 4.452

10. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.

Authors: Katsuhiro Masago; Shiro Fujita; Miho Muraki; Akito Hata; Chiyuki Okuda; Kyoko Otsuka; Reiko Kaji; Jumpei Takeshita; Ryoji Kato; Nobuyuki Katakami; Yukio Hirata
Journal: BMC Cancer Date: 2015-11-16 Impact factor: 4.430